- Home
- AUDC vs CCCC Comparison
AUDC vs CCCC Comparison
Compare AUDC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- CCCC
- Stock Information
- Founded
- AUDC 1992
- CCCC 2015
- Country
- AUDC Israel
- CCCC United States
- Employees
- AUDC N/A
- CCCC N/A
- Industry
- AUDC Telecommunications Equipment
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- CCCC Health Care
- Exchange
- AUDC Nasdaq
- CCCC Nasdaq
- Market Cap
- AUDC 282.4M
- CCCC 175.1M
- IPO Year
- AUDC 1999
- CCCC 2020
- Fundamental
- Price
- AUDC $10.20
- CCCC $2.66
- Analyst Decision
- AUDC Buy
- CCCC Buy
- Analyst Count
- AUDC 3
- CCCC 3
- Target Price
- AUDC $11.67
- CCCC $8.00
- AVG Volume (30 Days)
- AUDC 91.9K
- CCCC 1.1M
- Earning Date
- AUDC 11-05-2025
- CCCC 10-30-2025
- Dividend Yield
- AUDC 3.83%
- CCCC N/A
- EPS Growth
- AUDC 3.22
- CCCC N/A
- EPS
- AUDC 0.46
- CCCC N/A
- Revenue
- AUDC $243,249,000.00
- CCCC $34,240,000.00
- Revenue This Year
- AUDC $2.52
- CCCC N/A
- Revenue Next Year
- AUDC $1.74
- CCCC N/A
- P/E Ratio
- AUDC $22.59
- CCCC N/A
- Revenue Growth
- AUDC N/A
- CCCC 16.55
- 52 Week Low
- AUDC $7.70
- CCCC $1.09
- 52 Week High
- AUDC $12.72
- CCCC $7.22
- Technical
- Relative Strength Index (RSI)
- AUDC 58.90
- CCCC 56.55
- Support Level
- AUDC $9.56
- CCCC $2.58
- Resistance Level
- AUDC $10.47
- CCCC $2.75
- Average True Range (ATR)
- AUDC 0.26
- CCCC 0.16
- MACD
- AUDC 0.11
- CCCC -0.01
- Stochastic Oscillator
- AUDC 80.00
- CCCC 63.46
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.